Success Metrics

Clinical Success Rate
80.0%

Based on 8 completed trials

Completion Rate
80%(8/10)
Active Trials
1(8%)
Results Posted
63%(5 trials)
Terminated
2(17%)

Phase Distribution

Ph phase_3
4
33%
Ph phase_4
1
8%
Ph phase_2
5
42%
Ph phase_1
2
17%

Phase Distribution

2

Early Stage

5

Mid Stage

5

Late Stage

Phase Distribution12 total trials
Phase 1Safety & dosage
2(16.7%)
Phase 2Efficacy & side effects
5(41.7%)
Phase 3Large-scale testing
4(33.3%)
Phase 4Post-market surveillance
1(8.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

80.0%

8 of 10 finished

Non-Completion Rate

20.0%

2 ended early

Currently Active

1

trials recruiting

Total Trials

12

all time

Status Distribution
Active(2)
Completed(8)
Terminated(2)

Detailed Status

Completed8
Terminated2
Not yet recruiting1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
1
Success Rate
80.0%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (16.7%)
Phase 25 (41.7%)
Phase 34 (33.3%)
Phase 41 (8.3%)

Trials by Status

not_yet_recruiting18%
recruiting18%
terminated217%
completed867%

Recent Activity

1 active trials
Showing 5 of 12
recruitingphase_3

Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients

NCT06918002
not_yet_recruitingphase_2

Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure

NCT07085728
completedphase_3

Trial of Three Stem Cell Mobilization Regimens for Multiple Myeloma

NCT01146834
completedphase_4

Pilot Study of Velcade® in IgA Nephropathy

NCT01103778
completedphase_3

Bortezomib (Velcade®), Lenalidomide (Revlimid®) and IV Busulfan (Busilvex®) in Patients Under 65 Years Old

NCT01916252
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT06918002Phase 3

Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients

Recruiting
NCT07085728Phase 2

Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure

Not Yet Recruiting
NCT01146834Phase 3

Trial of Three Stem Cell Mobilization Regimens for Multiple Myeloma

Completed
NCT01103778Phase 4

Pilot Study of Velcade® in IgA Nephropathy

Completed
NCT01916252Phase 3

Bortezomib (Velcade®), Lenalidomide (Revlimid®) and IV Busulfan (Busilvex®) in Patients Under 65 Years Old

Completed
NCT00103506Phase 3

Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma

Completed
NCT01062230Phase 2

Bone Effect of Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma

Terminated
NCT00891033Phase 1

Panobinostat/Velcade in Multiple Myeloma

Terminated
NCT00373906Phase 2

Velcade in MALT Lymphoma Patients

Completed
NCT00369226Phase 1

Bortezomib Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease (GVHD) After Mismatched Allogeneic Non-Myeloablative Blood Stem Cell Transplantation

Completed
NCT01830465Phase 2

VELCADE® Plus Rituximab in Non Hodgkin's Follicular Lymphoma

Completed
NCT00142129Phase 2

Bortezomib (Velcade) in Waldenstrom's Macroglobulinemia

Completed

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12